Citigroup Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $62

Benzinga Newsdesk www.benzinga.com Positive 82.1%

Neg 0% Neu 0% Pos 82.1%

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $60 to $62.